BioAge Labs (NASDAQ:BIOA) Stock Price Down 4.1% – Should You Sell?

BioAge Labs, Inc. (NASDAQ:BIOA) fell 4.1% on Thursday . The company traded as low as $18.46 and last traded at $19.3030. 852,431 shares changed hands during trading, a decline of 20% from the average session volume of 1,070,947 shares. The stock had previously closed at $20.12.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Citigroup raised their price objective on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. Finally, Wall Street Zen raised shares of BioAge Labs from a “sell” rating to a “hold” rating in a research note on Sunday, January 18th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioAge Labs has an average rating of “Hold” and a consensus target price of $15.00.

BioAge Labs Price Performance

The stock has a market cap of $674.43 million, a PE ratio of -12.38 and a beta of 1.38. The business has a 50 day moving average price of $13.43 and a two-hundred day moving average price of $8.18.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.11. The firm had revenue of $2.05 million for the quarter.

Insider Buying and Selling

In other news, CEO Kristen Fortney sold 233,107 shares of BioAge Labs stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total value of $4,223,898.84. Following the sale, the chief executive officer directly owned 976,949 shares in the company, valued at approximately $17,702,315.88. This trade represents a 19.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the transaction, the chief financial officer directly owned 22,408 shares in the company, valued at $441,437.60. This trade represents a 54.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 347,004 shares of company stock valued at $5,673,859 over the last ninety days. 20.82% of the stock is owned by insiders.

Institutional Trading of BioAge Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BIOA. Russell Investments Group Ltd. bought a new position in BioAge Labs in the 3rd quarter worth $27,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of BioAge Labs during the second quarter valued at about $27,000. Nisa Investment Advisors LLC raised its stake in BioAge Labs by 4,219.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock worth $135,000 after buying an additional 10,000 shares in the last quarter. Bank of America Corp DE lifted its holdings in BioAge Labs by 46.3% in the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after acquiring an additional 5,976 shares in the last quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.